Treatment preference and recruitment to pediatric RCTs:A systematic review by Beasant, Lucy et al.
                          Beasant, L., Brigden, A., Parslow, R., Apperley, H., Keep , T., Northam, A.,
... Crawley, E. (2019). Treatment preference and recruitment to pediatric
RCTs: A systematic review. Contemporary Clinical Trials Communications,
14, [100335]. https://doi.org/10.1016/j.conctc.2019.100335
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.conctc.2019.100335
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.sciencedirect.com/science/article/pii/S2451865418300838 . Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Contents lists available at ScienceDirect
Contemporary Clinical Trials Communications
journal homepage: www.elsevier.com/locate/conctc
Treatment preference and recruitment to pediatric RCTs: A systematic
review
L. Beasanta,∗, A. Brigdena, R.M. Parslowa, H. Apperleyb, T. Keepc, A. Northamd, C. Wraye,
H. Kingf, R. Langdone, N. Millse, B. Youngg, E. Crawleya
a Centre for Academic Child Health, Bristol Medical School, University of Bristol, UK
bDepartment of Academic Paediatrics, Royal Alexandra Children's Hospital, Brighton and Sussex University Hospitals, UK
cNHS Greater Glasgow and Clyde, UK
dDepartment of Primary Care and Public Health, Royal Sussex County Hospital, Brighton and Sussex Medical School, UK
e Population Health Sciences, Bristol Medical School, University of Bristol, UK
f Bristol Royal Hospital for Children, University Hospitals Bristol NHS Trust, UK
g Institute of Psychology, Health and Society, University of Liverpool, UK
A R T I C L E I N F O
Keywords:
Randomised controlled trial
Recruitment
Pediatric
Parent
Treatment preference
A B S T R A C T
Background: Recruitment to pediatric randomised controlled trials (RCTs) can be a challenge, with ethical issues
surrounding assent and consent. Pediatric RCTs frequently recruit from a smaller pool of patients making
adequate recruitment difficult. One factor which influences recruitment and retention in pediatric trials is pa-
tient and parent preferences for treatment.
Purpose: To systematically review pediatric RCTs reporting treatment preference.
Methods: Database searches included: MEDLINE, CINAHL, EMBASE, and COCHRANE.
Qualitative or quantitative papers were eligible if they reported: pediatric population, (0–17 years) recruited
to an RCT and reported treatment preference for all or some of the participants/parents in any clinical area. Data
extraction included: Number of eligible participants consenting to randomisation arms, number of eligible pa-
tients not randomised because of treatment preference, and any further information reported on preferences
(e.g., if parent preference was different from child).
Results: Fifty-two studies were included. The number of eligible families declining participation in an RCT be-
cause of preference for treatment varied widely (between 2 and 70%) in feasibility, conventional and preference
trial designs. Some families consented to trial involvement despite having preferences for a specific treatment.
Data relating to ‘participant flow and recruitment’ was not always reported consistently, therefore numbers who
were lost to follow-up or withdrew due to preference could not be extracted.
Conclusions: Families often have treatment preferences which may affect trial recruitment. Whilst children ap-
pear to hold treatment preferences, this is rarely reported. Further investigation is needed to understand the
reasons for preference and the impact preference has on RCT recruitment, retention and outcome.
1. Introduction
Successful recruitment and retention is crucial in randomised con-
trolled trials (RCT) research [1–3]. Recruitment problems can delay or
prevent trial completion [4–11], and post-randomisation drop-out can
lead to the loss of statistical power to measure differences between
treatment arms [4,7,9,12,13]. Exploration of recruitment and retention
issues in trials is extensive. Factors highlighted as important during the
design and implementation phases of RCTs include: trial design, in-
centives, patient characteristics, support for recruiters, and patient and
recruiter preferences for treatment [1,2,4,14–18].
If patients have a preference for treatment offered in an RCT they
may decline randomisation to access treatment outside the trial. The
external validity of an RCT may be compromised if patients with
treatment preferences decline to participate, and bias is possible if
uneven numbers of participants drop-out or cross-over between treat-
ment arms [19,20]. Preferences can also affect adherence to treatment
arms in RCTs where blinding to trial interventions is not possible
[21,22]. Trials recruiting adult patients have reported treatment pre-
ference as a barrier to recruitment [23–25], but there it is a lack of
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evidence in relation to the ways in which preferences for trial inter-
ventions might affect recruitment and retention in pediatric trial set-
tings [18].
Systematic reviews investigating the effects of treatment preference
in RCTs have largely focused on trials recruiting adult patients [26,27].
A systematic review published in 2005 investigated the effects of par-
ticipants' and professionals' preferences on recruitment, retention, and
treatment outcomes. This review extracted data from 34 RCTs, but only
four of the included trials had recruited pediatric-patients. Preferences
were found not to significantly affect trial validity, but preferences did
influence patients’ willingness to participate [26]. The second sys-
tematic review published in 2008 focused on musculoskeletal trials,
extracting data from 18 RCTs none of which recruited pediatric patients
[27]. This review investigated the effect of preference on attrition and
outcomes but did not investigate the effect of treatment preference on
recruitment. It found that patient preferences for treatment were as-
sociated with treatment effects.
We cannot assume treatment preferences will have the same impact
on recruitment to pediatric trials as has been shown in adult trials.
Pediatric trials involve the combined preferences of parent(s), patient
and recruiting clinicians, in addition to a more complex consent process
[28,29]. There will also be variation in the extent to which young
people participate in decision-making and the recruitment process,
depending on the nature and severity of their illness [30–35]. The
purpose of this systematic review was to identify pediatric RCTs where
treatment preferences are reported, and describe the impact of pre-
ference on recruitment and retention.
2. Methods
A review protocol was developed and registered with PROSPERO:
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=
CRD42015015942. The review protocol also included methodology
relating to the syntheses of qualitative data extracted from papers
identified via this systematic literature search, which will be submitted
for publication separately [36].
2.1. Study eligibility and inclusion criteria
Scoping exercises were used to define and refine relevant search
terms using the PICOC model: Population, Intervention, Comparison,
Outcomes and Context [37]. Qualitative sub-studies embedded in RCTs
or quantitative primary and secondary outcome papers were eligible for
inclusion if they reported RCTs recruiting new-borns, children and
young people aged 0–17 years to an RCT, in any clinical area. Eligible
papers were also required to report treatment preferences for all or
some of the participants/parents. Database searches were limited to
1950–2014 inclusive.
2.2. Search strategy
A search strategy was developed with guidance from University of
Bristol data specialists (NIHR/CLAHRC West and Cochrane
Collaboration group), the search strategy can be found in Supplemental
Information, Appendix A. Database searches of MEDLINE, CINAHL,
Fig. 1. PRISMA [107] Systematic search of literature reporting treatment preference in pediatric RCTs.
L. Beasant, et al. Contemporary Clinical Trials Communications 14 (2019) 100335
2
EMBASE, and COCHRANE were carried out. Searches of relevant re-
ference lists, databases containing registered clinical trials (https://
www.ukctg.nihr.ac.uk/https://clinicaltrials.gov/ct2/home http://
www.anzctr.org.au/TrialSearch.aspx) and work not published in peer-
reviewed journals (http://proquest.umi.com/login) were carried out.
Authors were contacted to establish whether full RCT results had
been published, two provided copies of their papers [38,39] and three
confirmed that they had not [40–43].
2.3. Screening and data extraction
Each title and abstract was screened independently for inclusion by
two researchers using the systematic review platform Covidence [44].
Discrepancies were documented, discussed and resolved in regular
meetings by reviewers and a senior member of the study management
team (EC) to ensure eligibility criteria were understood and screening
queries resolved consistently. At the full text review stage papers were
read in chronological order by two researchers (LB and AB, HK, RL or
RP). Author(s) extracted relevant numeric data and/or descriptive re-
ports of treatment preference into an Excel template (see Supplemental
Information, Appendix B).
3. Results
3.1. Summary of included studies
Database searches retrieved 23,449 papers, and additional searches
yielded 101 papers. After deduplication, title and abstract screening
was carried out on 17,036 papers, and 676 were read in full, with 52
papers eventually included in analyses (see Fig. 1). Table 1 describes
the papers included in the systematic review. Twenty-seven papers
reported data from RCTs conducted in the UK [28,29,45–59] and
Europe [38,40,41,60–66], 16 from RCTs conducted in the USA and
Canada [39,42,43,67–79], seven in countries outside of North America
and Europe [30,80–85], and two papers reported RCTs collecting data
internationally [86,87]. Most papers were published from the year
2000 onwards (n=42). Of the 52 papers included, 24 described ‘pri-
mary’ trial outcomes and 28 were ‘secondary’ papers which explored
patient/parent experience of trial involvement, or reasons for declining,
consenting, and recruitment. Searches were carried out to locate pri-
mary trial papers for secondary papers included in the review and 18
were located [88–105]. It was not possible to find all the primary trial
papers because some secondary papers didn't explicitly use identifiable
trial names or registration numbers. Of the 52 papers, seven reported
findings from multiple trials [28–30,39,48,52,70], and two were ab-
stracts from poster presentations [40,41]. Forty-two of the papers re-
ported ‘conventional’ RCTs [28–30,38–43,45–47,49,50,52,
54–60,62,64,65,67–71,74,75,77–83,85–87], two of which were in the
feasibility or pilot stages [46,80]. Eight papers described RCTs with
parallel ‘preference’ arms at trial outset [51,53,61,66,72,73,84,106],
and two introduced preference arms due to slow recruitment [48,76].
3.2. Impact of treatment preference on recruitment – conventional RCTs
Table 2 describes data on preference from all included papers. Se-
venteen papers reported the number of eligible families declining parti-
cipation because of a preference for treatment, this ranged from 2 to 50%
in conventional trials [49,54–57,64,65,68,69,74,75,78,79,83,85–87],
and 4–70% in the two pilot/feasibility phase trials [46,80]. Eleven RCTs
reported the preferences of families who opted for trial participation
[38,40–43,49,58–60,67,77], these treatment preferences were either
expressed at enrolment or after randomisation. Five trials reported
withdrawal after randomisation [57,62,71,74,82]. Families either with-
drew consent or refused their allocated intervention, but only one of
these trials specifically attributed this to a preference for the alternate
treatment arm [71].
3.3. Impact of treatment preference – RCTs with non-randomised preference
arms
Eight papers reported RCTs which used non-randomised ‘preference
arms’ in addition to randomised treatment arms from the outset
[51,53,61,63,72,73,84,102]. All of these trials reported the number of
eligible families declining randomisation arms because of a preference
for treatment, this ranged from 11 to 55%. One of these trials was ex-
tended by two years to increase recruitment to randomised trial arms
[53]. Two additional trials introduced preference arms because families
declined participation because of preferences for treatment [48,76].
3.4. Patient or parent preference
Nine papers explicitly reported the treatment preferences of pa-
tients, as well as their parents [28,41–43,53,57,59,75,80]. Child/par-
ental views on a preferred treatment arm differed on three occasions
[28,42,53]. Twelve papers reported findings from trials involving
children under the age of six years, so did not include information on
preference from children [45,50,58,61–63,67,68,74,78,83,84].
3.5. Clinician preferences for trial treatments
Most studies did not comment on why families held a treatment
preference, but six papers reported different forms of clinician pre-
ference for a particular treatment which may have influenced patient
preference [28,41,63,77,84,85]. Two trials stated that staff experienced
discomfort with children's medication/intervention being selected by a
process of randomisation [28,84], one highlighted that ‘consent was
more likely when the recruiting physician was a member of the research
team’ [85] and in another, a parent whose child was randomised to a
splint treatment arm was told the day after randomisation by a clinician
outside the RCT that ‘all buckle fractures need to be casted’ [77]. Finally,
one trial reported that parents who refused randomisation did so be-
cause of; ‘a desire to have decisional control, and they trusted their physi-
cian's choice of treatment more than a computer's choice’ [109]. These
findings suggest that recruiters and treating clinicians may be an im-
portant influence on parent and patient treatment preferences when
families consider RCT participation.
4. Discussion
To our knowledge, this is the first systematic review that has spe-
cifically investigated whether treatment preference influences recruit-
ment into pediatric trials. The review has shown that families often
have preferences for treatment at recruitment, and some families con-
sent to trial involvement despite having preferences for a specific
treatment. The number of eligible families declining participation in an
RCT because of preference for treatment varied widely: From 2 to 70%
in feasibility RCTs, from 2 to 50% in conventional main RCTs, and from
11 to 55% in trials with preference arms. Declining accrual rates and a
loss of clinical equipoise led to the closure of two trials [48,74], and two
required extensions because of slow recruitment [53,87].
Several trials included in this systematic review introduced pre-
ference arms to improve recruitment. Patient preference trials (PPTs)
and comprehensive cohort designs [110,111], (in which participants
with a preference are offered their treatment of choice, and those
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Table 1
Included studies (n= 52).
Conventional RCTs (n= 42)
Author Paper type (primary or secondary papera) Participant age Aim
Allen 2013 [80] Primary (Feasibility) 13–17yrs Assessed feasibility of recruiting young women into an RCT of
caseload midwifery.
Allmark 2006 [45] Secondary Primary paper Azzopardi 2009
[90]
≥36wks Compared intensive care plus total-body cooling for 72 h with
intensive care without cooling among term infants with asphyxial
encephalopathy.
Banks 2012 [46] Primary (Pilot) 5–16yrs Assessed feasibility of carrying out a fully powered RCT comparing;
care of childhood obesity intervention (COCO) and a primary care
clinic intervention (PCC).
Barratt 2013 [81] Secondary Primary paper Wake 2009 [104] 5–10yrs In-depth understanding of why families chose not to participate in a
community-based study on childhood obesity.
Bauchner 1996 [67] Primary 3mth-6yrs Do parents prefer antibiotic administration for treatment of acute
otitis media by a single intramuscular (IM) injection or standard oral
therapy for 10 days.
Blickman 2013 [68] Primary 1–12yrs Assessed the impact of a Certified Child Life Specialist (CCLS) on
parent satisfaction, staff satisfaction, child satisfaction, and parent and
staff perceptions of child pain and distress in a pediatric imaging
department.
Byrne-Davis 2010 [47] Secondary Primary paper Vora 2013 [103] 2–11yrs Examined how recruitment looked to an observer and how it felt to
parents, (of children with low-risk acute lymphoblastic leukemia) to
identify how doctors' communication could promote or inhibit optimal
recruitment.
Caldwell 2003 [30] Secondary (Multiple RCTs) Not stated Explored parents' attitudes to children's participation in trials,
identifying factors that influenced decision making and perceived risks
and benefits. RCTs included oncology and renal: interventions not
defined.
Carvalho 2013 [82] Secondary Primary paper Moreira 2013
[99]
< 3yrs The understanding and perceptions of mothers regarding the informed
consent and randomisation processes linked to an RCT that compared
behavior management techniques for pediatric dental sedation.
Chappuy 2014 [38] Secondary Children - age not
stated
Parental and child understanding of RCT participation (Acute
lymphoblastic leukemia FRALLE 2000A protocol) and evaluations of
the readability of written documents provided.
Duncan 2004 [69] Primary 11mths-12yrs Effectiveness of osteopathic manipulation, acupuncture or wait list
control as a 6-month therapeutic adjunct for children with spastic
cerebral palsy.
Eiser 2005 [49] Secondary Primary paper Mitchell 2005
[98]
4–16yrs Mothers' (of children newly diagnosed with Acute Lymphoblastic
Leukemia: ALL) views regarding consent to randomised controlled
trials.
Forsander 1995 [60] Primary 12–15yrs Evaluation of family attitudes in relation to the two 3wk care systems
for diabetes management: early discharge from ward to training
apartment and treatment on a ward in pediatric clinic.
Glogowska 2001 [50] Secondary Primary paper Glogowska 2000
[94]
3–4yrs Reported attitudes of parents whose child took part in a speech and
language therapy RCT comparing immediate treatment and watchful
waiting.
Harth 1990 [83] Secondary Primary paper Van Asperen 1992
[101]
6mths-3yrs Double-blind, placebo-controlled trial of ketotifen, a new and
unlicensed (for Australia) oral asthma drug.
Hissink Muller 2011 [40] Secondary (poster presentation) Primary
paper Hissink Muller 2017 [96]
Children - age not
stated
Comparison of three treatment strategies, and feedback relating to
treatment preferences among parents of patients with recent onset
juvenile idiopathic arthritis.
Hissink Muller 2012 [41] Secondary (poster presentation) Primary
paper Hissink Muller 2017 [96]
12–18yrs Comparison of three treatment strategies, and feedback relating to
equipoise among parents and patients with recent onset juvenile
idiopathic arthritis.
Johnson 2007 [42] Secondary 10–18yrs (and
adults)
Assessed participant and parent experiences in the parenteral insulin
arm of the Diabetes Prevention Trial (DPT-Type 1).
Johnson 2009 [43] Secondary 10–18yrs (and
adults)
Assessed the experiences of participants and parents of children in the
oral insulin study of the Diabetes Prevention Trial (DPT-Type 1).
Jollye 2009 [52] Secondary (Multiple RCTs) Neonates Explored the thoughts and feelings of parents in their decision-making
process, in either choosing or declining to participate in neonatal
RCTs.
Levi 2000 [70] Secondary (Multiple RCTs) 2–18yrs Retrospective parent perceptions of communication of their child's
cancer diagnosis and the informed consent process.
Miner 2007 [71] Primary 6mth-17yrs To determine if nebulized fentanyl is a feasible alternative to IV
fentanyl for the treatment of acute pain in children presenting to the
emergency department (ED) with painful conditions.
Payne 2004 [54] Secondary 3–12yrs Views and preferences for anesthetic related issues important to
parents (and adults) who took part in a prospective RCT.
(PENTA) Paediatric European
Network for Treatment of AIDS
1999 [86]
Secondary (double-blind) Children - age not
stated
Described parents' experience of their child being enrolled in a HIV
infection RCT, including the degree to which it interfered with life,
and their feelings about use of deferred (placebo) and immediate
antiretroviral treatment.
Rovers 2000 [62] Primary 16-24mths The effectiveness of ventilation tubes on the language development in
infants with persistent otitis media with effusion (OME) compared to
watchful waiting (WW).
(continued on next page)
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Table 1 (continued)
Conventional RCTs (n= 42)
Author Paper type (primary or secondary papera) Participant age Aim
Sammons 2007 [55] Secondary Primary paper Atkinson 2007
[89]
6mth-16yrs Parental views on the informed consent process, information provided,
reasons for taking part and willingness to participate in future
research. Compared motives of British and European parents.
Sandler 2014 [56]z Primary 12–18yrs Effectiveness of 3 methods of orthodontic anchorage supplementation,
reporting orthodontists' and patients' values.
Sartain 2002 [57] Primary 6wks-12yrs Assessed the clinical effectiveness of a pediatric hospital at home
service compared to conventional hospital care.
Schuttelaar 2010 [64] Primary ≤16yrs Compared the level of care from nurse practitioners with care
delivered by dermatologists.
Sederberg-olsen 1998 [65] Secondary (double blind) Primary paper
Balle 1998 [91]
1–10yrs Evaluated the efficacy of amoxicillin-clavulanate and penicillin-V in
the treatment of secretory otitis media (SOM).
Shilling 2011 [28] Secondary (Multiple RCTs) MASCOT:
funding extension application rejected &
trial closed prematurely [97]
MENDS [88]
POPs [still recruiting]
TIPIT [108]
MASCOT: 6–15yrs
MENDS: 3–15yrs
POP: 4–18yrs
TIPIT: < 28wks
Identify strategies to improve recruitment and trial conduct, by
comparing practitioners' and parents' accounts of the invitation to
enter a child into clinical trials.
Snowdon 1997 [58] Secondary Primary paper UK Collaborative
ECMO Trial Group [95]
Neonates Exploration of parental reactions to random allocation of treatment in
a neonatal RCT comparing two methods of life support; conventional
management (CM) and extracorporeal membrane oxygenation
(ECMO). Recruitment was stopped early, because data showed a clear
advantage with ECMO.
Spandorfer 2005 [74] Primary Loss of clinical equipoise and
declining accrual rates led to trial
termination.
8wk-3yrs Compare oral rehydration therapy (ORT) and intravenous fluid
therapy (IVF) in the treatment of viral gastroenteritis.
Sureshkumar 2012 [85] Secondary Primary paper Craig 2009 [92] < 18yrs To identify modifiable and unmodifiable factors associated with
parental consent to a trial investigating long-term, low-dose antibiotics
in preventing recurrent urinary tract infection.
Tercyak 1998 [75] Secondary Primary paper Diabetes Control
Complications Trial Research Group [93]
11–18yrs Identify reasons/characteristics of adolescents who refuse or consent
to participate in an RCT of intensive therapy (IT) for insulin-dependent
diabetes mellitus.
Willey 2005 [59] Primary 4–16yrs Efficacy of oral or rectal route administered analgesia for post-
operative pain.
Williams 2013 [77] Primary 2–17yrs Compared cast versus splint for distal radial buckle fractures in
children in terms of parental and patient satisfaction, convenience and
preference.
WoodgateZ 2010 [39] Secondary (Multiple RCTs) 6mth-15yrs In-depth understanding of Canadian parents' participation in decisions
about childhood cancer clinical trials.
Woolfall 2013 [29] Secondary (Multiple RCTs)
MASCOT [97] funding extension
application rejected & trial closed
prematurely.
MENDS [88]
POPs [still recruiting]
TIPIT [108]
MASCOT: 6–15yrs
MENDS: 3–15yrs
POP: 4–18yrs
TIPIT: < 28wks
Explored how a parent's understanding of a trial might be associated
with the way that the trial was explained during the discussion with a
practitioner.
Wright 2005 [87] Primary
Recruitment was expected to take 3yrs but
took 6yrs.
4–10yrs Investigated early application hip spica compared with external
fixation in pediatric femoral fractures. Recruitment was expected to
take 3yrs but took 6yrs.
Wynn 2010 [78] Secondary
Primary paper Wang 2011 [105]
< 18mths In response to slow recruitment study coordinators evaluated factors
that affected enrollment and accrual.
Young 2006 [79] Secondary 7–17yrs Reported results of two studies of social phobia, assessing the extent to
which parental reluctance toward medication resulted in pre-
treatment attrition in; behavioural, fluoxetine and placebo groups.
RCTs with non-randomised preference arms (n = 10)
Cunningham 2011 [48] Secondary Trial 1: preference arm added
and trial terminated early due to inadequate
sample size.
Adolescents (age
not stated)
Reported two RCTs, both terminated early due to inadequate sample
size. Trial 1: Multi-center Orthodontic RCT which compared two
different methods of treating a specific type of malocclusion in
adolescents. (Trial 2: RCT, no preference data).
Gowers 2010 [51] Primary 12–18yrs Compared the clinical effectiveness of inpatient against outpatient
treatment and of generalist against specialist management.
Lock 2010 [53] Primary Trial extended from 5 to 7yrs to
increase patient recruitment.
4–15yrs An embedded qualitative study informed the development of the RCT,
it explored patient/parent(s) preferences for different treatment
options in patients with recurrent sore throats who had recently been
referred to ENT clinic. Extended from 5 to 7yrs to increase patient
recruitment.
Mattila 2007 [61] Primary ≤2yrs Assessed adenoidectomy in connection with tympanostomy compared
with tympanostomy only in preventing otitis media in children.
Paradise 1984 [72] Primary 3–15yrs Assessed the efficacy of tonsillectomy and adenoidectomy.
Paradise 1990 [73] Primary 1–15yrs Assessed the efficacy of adenoidectomy, comparing surgical and non-
surgical management, with equivalent non-randomised preference
arms.
(continued on next page)
L. Beasant, et al. Contemporary Clinical Trials Communications 14 (2019) 100335
5
without a preference have their treatment allocated randomly) offer the
opportunity to investigate the effects of preference on recruitment,
validity and treatment outcome [26,27,112]. Although this is one way
of dealing with patients’ preferences for treatment, this design has a
number of disadvantages. PPTs often require larger numbers of pa-
tients. In extending trial duration to meet recruitment targets for the
randomised arms, they may reduce external validity and gen-
eralisability of results. Also, such designs do not necessarily improve
informed consent [53,110,111,113–115].
A key strength of this review is that a large number of papers were
screened for inclusion by two reviewers at all stages in the review
process. This review was enriched by the inclusion of a wide range of
papers, including data from papers reporting primary trial outcomes,
and papers reporting qualitative findings on patient or parent experi-
ences of trial involvement, and reasons for decline, consenting and
recruitment. Limitations include the fact that seven papers reported
findings from multiple trials in one paper [28–30,39,48,52,70], and
many of the papers reporting qualitative findings did not include full
CONSORT flow diagrams, therefore data on those who were lost to
follow-up or withdrew due to preference could not be extracted. The
effect that treatment preference has on retention in pediatric trials re-
quires further investigation. If trial acronyms or references were pro-
vided in secondary papers, we carried out a search for each related
primary RCT outcome paper, but only 18/28 additional papers were
located. Data relating to ‘participant flow and recruitment’ was not
always reported consistently in primary RCT outcome papers. One
paper reported that 76 participants were allocated to treatment arms,
but only 68 then entered the RCT, presumably eight withdrew post-
randomisation but reasons for this were not provided [46]. A lack of
standardised detail in the reporting of recruitment and retention
methodology in RCTs has also been highlighted previously in a sys-
tematic review of behavioural interventions recruiting dyads (adult
patients and their support person) [116].
Parental reasons for strongly held treatment preferences include
concerns about side effects and attitudes towards new ‘experimental’ or
‘placebo’ interventions [55,117,118]. Although altruism is often cited
as a reason for RCT participation, there is also poor parental under-
standing of the process of randomisation and perceived personal benefit
for their child [14,119]. In pediatric trials, parents and children are
often both involved in receiving information about the trial and making
a decision about whether to take part, with support from a recruiting
clinician [120,121]. Our findings showed that parents' preferences are
reported more frequently than children's preferences. Only nine papers
reported child preference, even though the majority of included trials
were conducted with children and young people who were old enough
to assent to RCT involvement and express their views on treatment.
Children's preferences for treatment differed from parental views on
three occasions [28,42,53]. Older children and teenagers have reported
different views from their parents on the acceptability of treatment and
participation in asthma research protocols [122]. This is not consistent
with guidance suggesting young people's voices need to be more widely
heard [35,123], or approaches to communication which aim to support
personal autonomy instead of isolated ‘independence’ of choice in de-
cision-making [124,125].
Although this systematic review was not seeking to report clinician
preference for treatment in pediatric RCTs, a small number of studies
did report that members of the recruiting/treating teams held pre-
ferences. The impact of clinician preference has been described as af-
fecting pediatric trials [26,126]. In one trial 63% of parents said the
doctors recruiting them had influenced their decision to participate
[55]. Clinician preference has also been shown to influence recruitment
in adult trials [4,127–129]. More research should be carried out to
investigate the influence of recruiting professionals’ preferences for
treatment on the decision-making process of families.
5. Conclusions
This systematic review shows that treatment preference can be a
barrier to recruitment to pediatric RCTs. In some cases this can result in
the need to change the design of the trial (introduction of preference
arms), extend recruitment or result in trial closure. Further investiga-
tion is needed to understand the impact treatment preference has on
retention, and on the outcomes under investigation in pediatric trials.
Exploration of the reasons for parent and child preferences would also
be beneficial to ensure that families are fully informed when making
decisions about RCT participation.
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Table 1 (continued)
Conventional RCTs (n= 42)
Author Paper type (primary or secondary papera) Participant age Aim
Reddihough 1998 [84] Primary 12-36mths Compared conductive education (CE) program with equivalent
intensity traditional neurodevelopmental programs of rehabilitation
for young children with Cerebral Palsy.
Rovers 2001 [106] Primary 9–12mths Compared ventilation tubes (VT) and watchful waiting (WW) in the
management of patients with otitis media with effusion. The
generaliszability of randomised patients with eligible non-randomised
patients was studied via preference arms.
Weinstein 2013 [76] Primary Preference arms added after 3yrs of
recruitment.
10–15yrs The effectiveness of bracing, compared with observation in preventing
progression of the curve to 50° or more in idiopathic scoliosis patients,
with equivalent non-randomised preference arms.
Van Wijk 2014 [66] Secondary Primary paper Van Wijk 2014
[102]
4.5–6.5mths Primary: Effectiveness of helmet therapy for positional skull
deformation compared with the natural course of the condition
Secondary: Assess parents' decision for helmet therapy in infants with
skull deformation.
a Primary papers were defined as those reporting primary RCT outcome(s). Secondary papers were those reporting embedded/related studies (e.g. qualitative)
describing patient/parent experience of trial involvement, reasons for decline, consenting and recruitment.
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Table 2
Number of eligible participants recruited to trial, and those not randomised due to treatment preference.
Conventional RCTs (n= 42)
Author Number of eligible participants
consenting to randomisation arms
Number of eligible patients not randomised because of
treatment preference n (%)
Is preference expressed by patients (in
addition to parents)
Allen 2013 1 (10%) (Feasibility) 7 (70%) Yes (only patient preference reported)
Allmark 2010 325 (81%) Unclear, preference reported qualitatively [45]
‘30 declined’ ‘45 other reasons’ [90]
n/a neonates
Banks 2012 76 (50%) (Pilot) 6 (4%) No
Barratt 2013 258 (33%) Not reported.
9 (26%) of non-responders reported concern with being in
either the intervention or control group, but only 37/305
non-responders replied to question.
No
Bauchner 1996 648 (total eligible not reported) Not reported.
Parents were asked their preference at enrollment and 551
(85%) of those randomised preferred single-dose therapy
over standard therapy.
n/a children under 6yrs
Blickman 2013 142 (88%) 4 (2%) Unclear (patients aged 4yrs + were asked
to complete a standardised study
instrument)
Byrne-Davis 2010 521 (71%) [103] Not reported, preference reported qualitatively [47]
215 (29%) not randomly assigned; 97 refused, 7 had Down's
syndrome, 4 because of toxic effects, 28 other reason, 79
unknown [103]
No
Caldwell 2003 Not reported (multiple trials) Not reported, preference reported qualitatively. Participant age not stated.
Carvalho 2013 Unclear 48 'recruited' [82] 44
(100%) 'randomised' [99]
Not reported, preference reported qualitatively [82]
3 (7%) parents refused allocated interventions post-
randomisation in x 2 trial arms [99]
No
Chappuy 2014 Not reported Not reported.
Some Parents felt that standard treatment was the best arm
for their child because it was less risky
Participant age not stated.
Duncan 2004 50 different participants
randomised. Total eligible not
reported.
8 (between 12 and 16%) No
Eiser
2005
1621 (90%) [98] 181 (10%) declined randomisation
(opted for PRED; 165 DEXA; 16) [98]
Preference reported qualitatively, 16 (32%) ‘agreed
reluctantly to randomisation’ [49].
No
Forsander 1995 38 (93%) Not reported
Immediately after randomisation 3 families in the control
arm reported that they would have preferred the family
therapeutic care arm.
No
Glogowska 2001 159 (69%) [94] Not reported, preference reported qualitatively [50]
Declined trial in total 70 (31%) [94]
n/a children under 4yrs
Harth 1990 72 (55%) 40 (30%) families declined because of ‘concern about side
effects of the new drug’ (ketotifen) 60 declined in total.
n/a children under 3yrs
Hissink Muller 2011 Not reported Not reported.
41% participating parents reported a preference for therapy
with methotrexate and etanercept and 6% had hoped against
assignment to this group. Primary aversion was highest
(25%) in the prednisone group [40]. Declined trial n= 38
(29%) [96].
No
Hissink Muller 2012 Not reported Not reported.
65% participating parents reported a preference for therapy
with etanercept. 5 parents and 2 patients participated in the
study to access treatment with etanercept, as initial
treatment was not possible nor reimbursed in daily practice.
Yes
Johnson 2007 Not reported Not reported.
Participating families stated: Close monitoring arm - 27%
parents and 70% participants were glad to be in that arm.
74% parents and 35% participants sometimes wished they
had been assigned the intervention arm. Intervention arm -
53% parents and 21% participants were glad to be in that
arm. 25% parents and 47% participants sometimes wished
they had been assigned the closely monitored arm.
Yes
Johnson 2009 Not reported Not reported.
Participating families were blinded to treatment but were
asked which treatment arm they would have preferred. 60%
parents and 53% participants chose the capsule condition.
8% parents and 21% participants chose the no intervention
condition. Very few participants and parents (3%) chose the
insulin injection condition.
Yes
Jollye 2009 Not reported, multiple trials. Not reported, preference reported qualitatively. n/a neonates
Levi 2000 Not reported, multiple trials. Unclear.
3 (13.6%) stated they declined participation because they
felt more comfortable with a “tried and true” method.
No
(continued on next page)
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Table 2 (continued)
Conventional RCTs (n= 42)
Author Number of eligible participants
consenting to randomisation arms
Number of eligible patients not randomised because of
treatment preference n (%)
Is preference expressed by patients (in
addition to parents)
Miner 2007 41 (82%) Unclear.
Declined randomised 9 (18%) reasons not reported. After
allocation 4 (10%) parents requested that their child receive
nebulized fentanyl rather than the assigned IV fentanyl.
No
Payne 2004 Unclear
Calculated as; 322 (69%) of
eligible patients. Paper reports
recruitment rate of 75%
59 (50%) ‘Around half of the eligible participants who
refused to participate did so because there was a 50% chance
of the child being randomised to the inhalational induction
arm’.
No
(PENTA) Paediatric European
Network for Treatment of
AIDS 1999
197 4 (3%) parents stated explicitly that they were concerned
with the use of placebo.
No
Rovers 2000 187 Not reported.
19 (10%) parents withdrew consent straight after
randomisation (15 in ventilation tubes arm and 4 in watchful
waiting arm). 10 (5%) children in the watchful waiting arm
were treated with ventilation tubes.
n/a children under 2yrs
Sammons 2007 Unclear
245 'randomised’ [55]
252 (85%) ‘randomised’ [89]
25 (9%) declining families stated they wanted a specific
treatment (IV; 20 or oral; 5) [55]
43 (15%) declined to take part; n=6 (2%) excluded post
randomisation reasons: 4 withdrawn by parents/2 by
clinician (no further detail provided) [89].
No
Sandler 2014 78 (87%) 7 (8%) Three did not want to wear headgear for anchorage,
three did not want the Nance button palatal arches, but only
one patient did not want to take part because he or she was
unhappy at “the thought of temporary anchorage devices”.
No
Sartain 2002 399 (86%) 10 (2%)
7 families withdrew from ‘hospital care’ arm because they
wanted the ‘hospital at home’ arm
Yes
Schuttelaar 2010 160 4 (2%) Preferred only dermatologist (n = 2), preferred only
nurse practitioner (n = 2).
No
Sederberg-olsen 1998 429 120 (10%) parents insisted that the child had grommet
insertion performed at the time of randomisation.
No
Shilling 2011 MASCOT:
63 [97]
MENDS:
146 (84%) [88]
POP: [still recruiting]
TIPIT:
153 (57%) [108]
Unclear, preference reported qualitatively.
MASCOT Assessed for eligibility (n = 898), Not registered
(n = 732), Excluded (n = 103) [97].
MMENDS 27 (16%) assessed for eligibility but not
randomised: ‘declined 11’ ‘other 16’ [88].
TIPIT 57 (21%) assessed for eligibility but not randomised:
‘refused’ [105].
Yes
Snowdon 1997 185 (79%) [95] Unclear.
‘majority of parents had a keen preference for ECMO
treatment arm’. Preference reported qualitatively [58].
48 (21%) were registered but not randomised; 14 died, 19
improved and 15 parents refused trial participation [95].
n/a neonates
Spandorfer 2005 73 24 (7%)
A further 3 parents refused participation after randomisation
to oral rehydration therapy before starting treatment.
n/a children under 3yrs
Sureshkumar 2012 412 (37%) [85] 214 (19%) Prefer antibiotics 71/Prefer no antibiotics 143
[85].
Primary paper reports patients excluded because
‘participation refused by parent’ 1935 [92]
No
Tercyak 1998 56 2 (5%) Yes (only patient preference reported)
Willey 2005 31 Not reported.
19/31 patients completed a preference questionnaire/10
(43%) preference for oral, 2 (9%) for suppositories, 7 (30%)
no preference/preference for oral more pronounced among
girls 5 (83%).
Yes
Williams 2013 94 Not reported.
A significantly larger percentage of parents and patients in
the cast group reported that they would not choose the same
method of immobilization again at all time points (baseline,
days; 1, 3, 7, 21 after injury).
No
Woodgate 2010 Not reported (multiple trials) Not reported, preference reported qualitatively. n/a neonates
Woolfall 2013 MASCOT:
63 [97]
MENDS:
146 (84%) [88]
POP: [still recruiting]
TIPIT:
153 (57%) [108]
Unclear, preference reported qualitatively.
MASCOT Assessed for eligibility (n = 898), Not registered
(n = 732), Excluded (n = 103) [97].
MMENDS 27 (16%) assessed for eligibility but not
randomised: ‘declined 11’ ‘other 16’ [88].
TIPIT 57 (21%) assessed for eligibility but not randomised;
‘refused’ [105].
No
Wright 2005 108 (46%) 41 (33%) No
Wynn 2010 234 (29%) 2% unwilling to take placebo. n/a children under 2yrs
(continued on next page)
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